Drugs / telomerase: 540-548 peptide
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00021164 | May 2001 → May 2004 | cutaneous melanoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | telomerase: 540-548 peptide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00021164 ↗ |
| Known as | telomerase: 540-548 peptide vaccine | “telomerase: 540-548 peptide vaccine emulsified in Montanide ISA-51 subcutaneously (SC) on day 1 of weeks 1-4 and 7-10.” NCT00021164 ↗ |
| Action | Deplete | “kill tumor cells” NCT00021164 ↗ |
| Modality | Vaccine | “Vaccines made from a peptide may make the body build an immune response and kill tumor cells.” NCT00021164 ↗ |
| Route | Subcutaneous | “telomerase: 540-548 peptide vaccine emulsified in Montanide ISA-51 subcutaneously (SC)” NCT00021164 ↗ |